GlobeNewswire · 财报与经营业绩·· 4 小时前AI 评分75
Harmony Biosciences Q3财报：WAKIX净收入2.69亿美元，全年指引维持10亿至10.4亿美元
Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
AI 导读
Harmony Biosciences公布Q3财报，WAKIX净收入为2.69亿美元，主要由400名新患者带动；公司重申全年营收指引为10亿至10.4亿美元。
来源：GlobeNewswire · 财报与经营业绩 · globenewswire.com